股本结构
单位：万股
| 公告日期 | 2025-11-12 | 2025-11-12 | 2025-08-12 | 2025-08-12 | 2025-06-27 | 2025-05-19 |
|---|---|---|---|---|---|---|
| 证券总股本 | 177.49 | 164.45 | 164.45 | 162.54 | 159.84 | 132.53 |
| 普通股本 | 177.49 | 164.45 | 164.45 | 162.54 | 159.84 | 132.53 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-07 | 2025-09-30 | 2025-08-08 | 2025-06-30 | 2025-06-27 | 2025-05-28 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-12 | 177.49 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-12 | 164.45 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock upon RSU vesting
|
2025-09-30 |
| 2025-08-12 | 164.45 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-08-12 | 162.54 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Decrease in common stock for rounding down of fractional shares to reflect the 1-for-50 reverse stock split
Issuance of common stock upon RSU vesting
Issuance of common stock and pre-funded warrants, net of issuance costs of $726Issuance of common stock upon exercise of pre-funded warrants
|
2025-06-30 |
| 2025-06-27 | 159.84 | 未披露 |
更多>>
Common stock offered 273,012 shares by the company
|
2025-06-27 |
| 2025-05-19 | 132.53 | 未披露 |
更多>>
Common Stock at a Reverse Stock Split of 1-for-50
|
2025-05-28 |
| 2025-05-06 | 6626.72 | 未披露 | 定期报告 | 2025-05-02 |
| 2025-05-06 | 6588.06 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock upon RSU vesting
|
2025-03-31 |
| 2025-03-13 | 6588.06 | 未披露 | 定期报告 | 2025-02-28 |
| 2025-03-13 | 6551.54 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Shares issued under ATM, net of issuance costs of $150
Issuance of common stock upon RSU vesting
Exercise of common stock options
Issuance of common stock and pre-funded warrants
Exercise of common stock warrants
Issuance of common stock under ESPP
|
2024-12-31 |
| 2024-11-12 | 6545.76 | 未披露 | 定期报告 | 2024-11-01 |
| 2024-11-12 | 6545.67 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock under ESPP
|
2024-09-30 |
| 2024-08-14 | 6545.67 | 未披露 | 定期报告 | 2024-08-01 |
| 2024-08-14 | 6545.57 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of common stock options
Exercise of pre-funded warrants
|
2024-06-30 |
| 2024-04-29 | 6096.49 | 未披露 | 定期报告 | 2024-04-03 |
| 2024-04-30 | 6096.48 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Exercise of common stock warrants
Exercise of common stock options
Exercise of pre-funded warrants
Shares issued under ATM, net of issuance costs of $150
Issuance of common stock upon RSU vesting
|
2024-03-31 |
| 2024-03-22 | 5974.31 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-03-22 | 5721.46 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Exercise of common stock options
Exercise of pre-funded warrants
Issuance of common stock and pre-funded warrants, net of issuance costs of $3,482
Shares issued under ATM, net of issuance costs of $172
Issuance of common stock upon RSU vesting
|
2023-12-31 |
| 2023-11-07 | 5256.31 | 未披露 | 定期报告 | 2023-11-01 |
| 2023-11-07 | 4954.56 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercise of common stock options
|
2023-09-30 |
| 2023-08-08 | 4954.56 | 未披露 | 定期报告 | 2023-08-01 |
| 2023-08-08 | 4954.50 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of common stock options
Issuance of common stock and pre-funded warrants, net of issuance costs of $3,332
|
2023-06-30 |
| 2023-07-07 | 4948.98 | 未披露 | 定期报告 | 2023-06-01 |
| 2023-04-25 | 3183.65 | 未披露 | 定期报告 | 2023-04-19 |
| 2023-05-12 | 3183.68 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of common stock options
Issuance of common stock upon RSU vesting
|
2023-03-31 |
| 2023-03-29 | 3182.98 | 未披露 | 定期报告 | 2023-03-01 |
| 2023-03-29 | 3182.77 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise of common stock options
Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244
Issuance of common stock upon RSU vesting
|
2022-12-31 |
| 2022-11-08 | 3182.70 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock upon RSU vesting
|
2022-09-30 |
| 2022-08-09 | 3182.64 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244
Issuance of common stock upon RSU vesting
|
2022-06-30 |
| 2022-04-13 | 3182.51 | 未披露 |
更多>>
1.On April 7, 2022, Lyra Therapeutics, Inc. entered into a Securities Purchase Agreement with the purchasers named therein, pursuant to which the Company agreed to sell securities to the Investors in a private placement.
Accordingly, pursuant to the Purchase Agreement, the Company agreed to sell (i) an aggregate of 18,815,159 shares of Common Stock to the Investors at the purchase price described in the preceding sentence.
|
2022-04-07 |
| 2022-03-09 | 1300.99 | 未披露 | 定期报告 | 2022-03-01 |
| 2022-03-09 | 1300.72 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of common stock options
Vesting of restricted common stock
|
2021-12-31 |
| 2021-11-09 | 1300.46 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of common stock options
|
2021-09-30 |
| 2021-05-11 | 1300.11 | 未披露 |
更多>>
From March 31, 2021 to May 3, 2021
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering
Issuance of common stock from initial public offering, net of issuance costs of $7,072
Vesting of restricted common stock
Issuance of common stock upon exercise of warrants
|
2021-05-03 |
| 2021-05-11 | 1296.28 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Exercise of common stock options
|
2021-03-31 |
| 2021-03-09 | 1294.76 | 未披露 | 定期报告 | 2021-03-01 |
| 2021-03-09 | 1293.24 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $201
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering
Issuance of common stock from initial public offering, net of issuance costs of $7,116
Vesting of restricted common stock
Issuance of common stock upon exercise of warrants
Exercise of common stock options
|
2020-12-31 |
| 2020-11-10 | 1292.70 | 未披露 | 定期报告 | 2020-11-02 |
| 2020-11-10 | 1292.48 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of common stock options
|
2020-09-30 |
| 2020-08-05 | 1292.46 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering
Issuance of common stock from initial public offering, net of issuance costs of $7,072
Vesting of restricted common stock
Issuance of common stock upon exercise of warrants
|
2020-06-30 |
| 2020-05-28 | 1292.46 | 未披露 | 定期报告 | 2020-05-22 |
| 2020-05-01 | 1239.96 | 未披露 |
更多>>
1.Common stock offered by us 3,500,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 230,860 shares of our common stock outstanding as of March 31, 2020
|
2020-05-01 |
From June 30, 2025 to September 30, 2025
Issuance of common stock upon RSU vesting
From March 31, 2025 to June 30, 2025
Decrease in common stock for rounding down of fractional shares to reflect the 1-for-50 reverse stock split
Issuance of common stock upon RSU vesting
Issuance of common stock and pre-funded warrants, net of issuance costs of $726Issuance of common stock upon exercise of pre-funded warrants
Common stock offered 273,012 shares by the company
Common Stock at a Reverse Stock Split of 1-for-50
From December 31, 2024 to March 31, 2025
Issuance of common stock upon RSU vesting
From December 31, 2023 to December 31, 2024
Shares issued under ATM, net of issuance costs of $150
Issuance of common stock upon RSU vesting
Exercise of common stock options
Issuance of common stock and pre-funded warrants
Exercise of common stock warrants
Issuance of common stock under ESPP
From June 30, 2024 to September 30, 2024
Issuance of common stock under ESPP
From March 31, 2024 to June 30, 2024
Exercise of common stock options
Exercise of pre-funded warrants
From December 31, 2023 to March 31, 2024
Exercise of common stock warrants
Exercise of common stock options
Exercise of pre-funded warrants
Shares issued under ATM, net of issuance costs of $150
Issuance of common stock upon RSU vesting
From December 31, 2022 to December 31, 2023
Exercise of common stock options
Exercise of pre-funded warrants
Issuance of common stock and pre-funded warrants, net of issuance costs of $3,482
Shares issued under ATM, net of issuance costs of $172
Issuance of common stock upon RSU vesting
From June 30, 2023 to September 30, 2023
Exercise of common stock options
From March 31, 2023 to June 30, 2023
Exercise of common stock options
Issuance of common stock and pre-funded warrants, net of issuance costs of $3,332
From December 31, 2022 to March 31, 2023
Exercise of common stock options
Issuance of common stock upon RSU vesting
From December 31, 2021 to December 31, 2022
Exercise of common stock options
Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244
Issuance of common stock upon RSU vesting
From June 30, 2022 to September 30, 2022
Issuance of common stock upon RSU vesting
From March 31, 2022 to June 30, 2022
Issuance of common stock and pre-funded warrants, net of issuance costs of $4,244
Issuance of common stock upon RSU vesting
1.On April 7, 2022, Lyra Therapeutics, Inc. entered into a Securities Purchase Agreement with the purchasers named therein, pursuant to which the Company agreed to sell securities to the Investors in a private placement.
Accordingly, pursuant to the Purchase Agreement, the Company agreed to sell (i) an aggregate of 18,815,159 shares of Common Stock to the Investors at the purchase price described in the preceding sentence.
From December 31, 2020 to December 31, 2021
Exercise of common stock options
Vesting of restricted common stock
From June 30, 2021 to September 30, 2021
Exercise of common stock options
From March 31, 2021 to May 3, 2021
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering
Issuance of common stock from initial public offering, net of issuance costs of $7,072
Vesting of restricted common stock
Issuance of common stock upon exercise of warrants
From December 31, 2020 to March 31, 2021
Exercise of common stock options
From December 31, 2019 to December 31, 2020
Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $201
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering
Issuance of common stock from initial public offering, net of issuance costs of $7,116
Vesting of restricted common stock
Issuance of common stock upon exercise of warrants
Exercise of common stock options
From June 30, 2020 to September 30, 2020
Exercise of common stock options
From March 31, 2020 to June 30, 2020
Conversion of redeemable convertible preferred stock to common stock upon closing of initial public offering
Issuance of common stock from initial public offering, net of issuance costs of $7,072
Vesting of restricted common stock
Issuance of common stock upon exercise of warrants
1.Common stock offered by us 3,500,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 230,860 shares of our common stock outstanding as of March 31, 2020